Coherus BioSciences (CHRS) Earnings Date & Reports

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building anÂ immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CHRS is expected to report earnings to fall 707.14% to $1.70 per share on May 08

Coherus BioSciences CHRS Stock Earnings Reports

Q1'25

Est.

$1.70

Q4'24

Beat

by $0.02

Q3'24

Beat

by $0.15

Q2'24

Beat

by $0.11

Q1'24

Missed

by $0.07

The last earnings report on March 10 showed earnings per share of -28 cents, beating the estimate of -30 cents. With 132.24K shares outstanding, the current market capitalization sits at 94.72M.

View a ticker or compare two or three

Compare

CHRS